AgelessRx Review: Rapamycin's Price Is Now Published

The one-sentence version

AgelessRx is the most research-literate operator in direct-to-consumer longevity — it funded, ran, and published a registered placebo-controlled rapamycin trial that missed its own primary endpoint¹, which is a level of self-disclosure no other row here attempts — and it charges no membership fee, which structurally beats every lab-gated program in our ranking. Update, August 2026: the gap that used to define this review has closed. Rapamycin, the flagship, now states its price plainly — "$65/month," with "Billed monthly | Shipped monthly" printed directly beneath it — where the site previously gave a floor with no terms attached. Metformin and NAD+ still carry the quarterly-plan and introductory-rate qualifiers described below, so the catalog isn't uniformly clean, but the product that decided this review's grade no longer has the problem it was graded on. For where prescription longevity telehealth sits in the wider market, see longevity clinics vs lab memberships vs Rx telehealth.

What AgelessRx is, and who it's for

AgelessRx is an Ann Arbor–based telehealth pharmacy-and-prescriber network built specifically around off-label longevity prescribing. You complete an online intake, a licensed clinician reviews it and decides whether to prescribe, and the prescription is filled by what the site calls a "partnering pharmacy" and shipped to you. There is no membership, no annual fee, and no mandatory diagnostic onboarding — you can buy one treatment and nothing else.

The catalog is the widest in our ranking: roughly four dozen line items spanning the longevity core (rapamycin, metformin, acarbose, low-dose naltrexone, NAD+ in four delivery formats, sermorelin, glutathione), a GLP-1 track, hormone and sexual-health products, dermatology, and a testing shelf that runs from a free online phenotypic calculator up to a $949 Galleri multi-cancer screen. Verified on AgelessRx's own treatment pages in July 2026.

The buyer this suits is specific: someone who already knows which molecule they want, wants a US-licensed prescriber and a pharmacy rather than a gray-market peptide vendor, and does not want to pay $129–$155 a month for a membership wrapper before the first pill ships. That is a real and underserved buyer, and AgelessRx serves them better than any lab-gated program does.

What it actually costs — and what the headline number leaves out

Here is the part that decides the grade, so we will be precise about what is published and what is not.

Metformin is the one product where AgelessRx spells out the terms in full. Its page reads: "Quarterly — $25 / month — billed $75 quarterly | shipped quarterly — 3-month supply per shipment." That is honest and complete: $25/month is real, but you pay $75 up front, three months at a time. No month-to-month option is offered.

NAD+ injections publish the trap explicitly, in small type. The headline is "Starting at $79 / mo," and directly beneath it: "Starting price applies to 3-mo plan. Monthly and 3-mo plans." Further down the same page, the disclaimer adds: "Introductory price applies to quarterly plan." So $79 is simultaneously (a) the quarterly-plan rate, not the monthly one, and (b) an introductory rate. As of our August 2026 check, the post-introductory rate is now disclosed too — $149/mo — closing part of the gap, though the monthly-plan (non-quarterly) price is still not stated separately.

Rapamycin — the flagship — now publishes real terms. As of our August 2026 check, the page states "$65/month" with "Billed monthly | Shipped monthly" printed directly under it — a genuine, computable monthly rate, not a floor with an unstated cadence. That resolves the specific gap earlier versions of this review flagged as AgelessRx's central failure.

The rest of the catalog still carries the "Starting at" construction more loosely: low-dose naltrexone $25, acarbose $55, sermorelin injection $99, glutathione injection $99, NAD+ nasal spray $125/mo, NAD+ patches $160/kit, microdosing semaglutide $99/mo, microdosing tirzepatide $159/month. On the testing shelf: a lab-based phenotypic blood test $75, a Core Longevity Panel $95, an at-home methylation saliva test $170. We have not re-verified the billing cadence on every one of these individually — rapamycin, metformin and NAD+ are the three we checked in full.

The catalog is not uniformly clean. AgelessRx discloses billing terms on rapamycin and metformin, and it's the two remaining products — NAD+'s introductory rate, and metformin's quarterly-only structure — that keep this row from a perfect price-transparency score, not an unpublished flagship. See our grading methodology and, for how the whole market prices itself, how much a longevity clinic costs.

What's included, what's extra

Genuinely included, and worth crediting:

• •The medical visit is free. No consult fee, no intake deposit. Several providers in our ranking charge one.
• •Shipping is free, quoted at 5–7 business days.
• •On rapamycin, the required blood work is included with the prescription. That matters: a product whose safe use depends on monitoring, sold with the monitoring bundled, is the right structure.
• •No membership. Nothing recurring sits on top of the medication itself.

Extra, or conditional:

• •Testing beyond the rapamycin monitoring is a separate purchase ($75–$949 depending on the panel).
• •Rapamycin is unavailable in NJ, NY, RI and HI.
• •Refills are conditional on compliance: "You must adhere to the required lab schedule to receive refills," and failure to comply "may result in your prescription being suspended or canceled." That is a restriction, and it is the right kind.

Clinical oversight: who prescribes, and what they check

AgelessRx names its clinical leadership, which most of this category does not. The site lists a Medical Director (Dr. Jenell Decker, MD), an Assistant Medical Director (Dr. Mirna Jadan, MD), a telehealth physician (Dr. Aaron Stecker, DO), a Medical Advisor (Dr. Terry Grossman, MD), and a VP of Operations and Applied Science with a PhD (Dr. Stefanie Morgan). Naming your prescribers is a meaningful signal in a field full of anonymous "licensed providers."

Two caveats a careful reader should hold. First, the Medical Director's listed longevity credential is from the American Academy of Anti-Aging Medicine (A4M) — a professional body, not one of the 24 member boards of the American Board of Medical Specialties, which recognizes no anti-aging or longevity specialty. That is not a knock on the physician; it is a fact about how thin formal credentialing is in this whole field, which we unpack in what is a longevity doctor. Second, fulfillment is described on the product pages as "a partnering pharmacy" without naming a facility, so you cannot verify which compounder made your vial. The compounding standard is stated, but you have to go looking for it: the FAQ says "all our partner pharmacies are certified 503A compounding pharmacies" — a clearer commitment than most providers here make, buried several clicks from where you buy. Worth knowing what that does and does not mean: 503A is a legal category rather than a quality certification, and 503A compounders are specifically not subject to current good manufacturing practice requirements.

The oversight that impressed us most is behavioral rather than structural: rapamycin refills are gated on lab compliance. A provider willing to cut off a paying subscriber who skips bloodwork is a provider whose oversight is not decorative.

The evidence behind what it sells

AgelessRx sells a menu of drugs with, collectively, no completed human trial showing extended lifespan. That is not a criticism unique to AgelessRx — it is true of the entire category — but a review has to say it plainly rather than let the catalog imply otherwise.

Rapamycin. The most reproducible lifespan extender in mice: fed late in life to genetically heterogeneous mice, it extended median and maximal lifespan in a landmark study². In humans, the best evidence is AgelessRx's own PEARL trial — 48 weeks, decentralised, double-blinded, placebo-controlled, 5 mg or 10 mg weekly. It found that intermittent low-dose rapamycin was relatively safe, with adverse events similar across groups. It also missed its primary endpoint: visceral adiposity did not change. Some secondary signals appeared in subgroups — lean tissue mass and self-reported pain improved in women on 10 mg — and the authors themselves concluded that future work "will aim to more comprehensively establish efficacy"¹. That is a fair and unusually candid readout, and we walk through it in detail in what the PEARL trial actually showed and rapamycin for longevity: hype vs evidence.

Metformin. The human longevity case rests on a mechanistic argument³ and one widely-cited observational finding — diabetic patients on metformin monotherapy showing better adjusted survival than matched non-diabetic controls in a UK database analysis⁴ — a result the authors themselves framed as a question, and one that confounding by indication can generate without any drug effect. Against it sits a randomized trial in which metformin blunted the gains from 12 weeks of aerobic training in older adults: attenuated improvements in whole-body insulin sensitivity and VO₂ max, and abrogated the exercise-driven increase in skeletal-muscle mitochondrial respiration⁵. Since cardiorespiratory fitness is among the strongest survival predictors ever measured⁶, a longevity drug that dulls exercise adaptation deserves more caution than a $25/month price tag conveys. Full treatment in metformin for longevity and rapamycin and metformin: the evidence.

NAD+. Oral nicotinamide riboside reliably raises NAD+ in healthy middle-aged and older adults and is well tolerated — that much is established⁷. What it does to you is a much thinner story: the strongest human trial to date improved 6-minute walk distance by about 17.6 meters in people with peripheral artery disease, in 90 participants, with the authors calling for a larger trial to confirm it⁸. That is a disease endpoint in a sick population, not a healthspan outcome in a well one. AgelessRx's NAD+ page nonetheless leads with "89% saw results by 2nd check-in" — an unblinded, self-reported figure from its own customer base, which is the weakest evidence class there is — and states that "Maintaining healthy NAD+ levels may slow down the aging process." Our full read is in NAD+ for longevity and do NAD+ and peptides actually extend lifespan.

Low-dose naltrexone. The one item on the menu with a genuine, if narrow, randomized case — a meta-analysis of four RCTs in 222 fibromyalgia patients found a significant reduction in pain scores and higher pressure-pain threshold versus placebo, though the fibromyalgia impact questionnaire and pain catastrophizing scale did not differ⁹. That is modest evidence for a pain indication. It is not evidence for longevity, and nothing about LDN's mechanism makes it one.

Sermorelin. A growth-hormone secretagogue, and the weakest thing on the menu. A landmark systematic review of growth hormone in healthy older adults found small body-composition changes, no proven functional benefit, and significantly more adverse events¹⁰. The downstream target, IGF-1, has a U-shaped relationship with mortality in meta-analysis — both low and high values associate with higher death rates¹¹ — so "raise it to feel younger" is not a coherent goal. Detail in peptides for longevity.

Where it's weak

1. Two of three checked products still price as a floor, not a price. Metformin's headline is a quarterly prepay; NAD+'s is quarterly and introductory. Rapamycin, the flagship, is the exception now — it publishes a real monthly rate — but until AgelessRx does the same for the rest of the catalog, a buyer still can't build the whole bill from the site alone.

2. Menu breadth is a conflict, not just a convenience. AgelessRx both recommends and dispenses roughly four dozen products, several of which (sermorelin, NAD+ in four formats, glutathione) have no meaningful human outcome data. A wide catalog run by the same entity that decides what you need is a structural incentive to find you something. That does not make the prescribing wrong — it means the burden of evidence honesty on the marketing copy is higher, not lower.

3. The research operation is a genuine asset and a genuine conflict. PEARL is AgelessRx-funded and AgelessRx-authored, testing a drug AgelessRx sells. The affiliations are disclosed on the paper, and the trial reported a null primary endpoint, which is about as strong a good-faith signal as an interested party can send. But a vendor's own trial on its own product is still a vendor's own trial, and the same site that publishes it also markets rapamycin as "the most promising longevity therapy today."

4. The pharmacy is classified but not named. AgelessRx's FAQ states "all our partner pharmacies are certified 503A compounding pharmacies" — a real, published standard, and this site's rubric gives full credit for exactly that claim. What's still missing is a facility name: "partnering pharmacies" tells you the standard, not which pharmacy actually filled your vial.

5. No included human support. There is no bundled nurse or dietitian contact of the kind a support-included program provides — the offer is prescriber plus pharmacy plus shipping.

Who should skip it

• •Anyone who wants the full annual cost of metformin or NAD+ before committing. Both still require an intake to get a real number — rapamycin no longer does.
• •Anyone shopping on price alone. A rate that only holds if you prepay a quarter is not comparable to a genuine flat monthly rate, and the two should not be lined up in a spreadsheet as if they were.
• •Anyone who wants diagnostics first. AgelessRx sells tests but is not built around them. If your goal is a broad panel with a clinician reading it, a lab membership does that better and cheaper — see our best longevity blood test services roundup and the Function Health review.
• •Anyone buying sermorelin as an anti-aging intervention. The evidence does not support it, at any price.
• •Anyone hoping a prescription substitutes for the boring levers. Cardiorespiratory fitness⁶ and grip strength — which outpredicted blood pressure across 17 countries in the PURE study¹² — are not on any AgelessRx order form.

How it compares to the rest of our ranking

Against the lab-gated memberships, AgelessRx wins on structure. Hone Health makes you buy a $65 biomarker test and then a $25 or $155 monthly membership before a prescription exists — but every drug on Hone's site is priced "From $X/mo + membership" with "No commitments. Cancel anytime" stated in plain language, so you can build the whole bill before you enter a card number. AgelessRx removes the membership and the lab gate entirely, and now discloses a real monthly rate on its flagship too — metformin and NAD+ are the two products where you still can't build the full bill from the site alone. Different trade-offs; a buyer should pick which gap they mind less.

Against Lifeforce — $349 starter plus $129/month for a narrow panel with a prescriber attached — AgelessRx is dramatically cheaper for someone who wants the prescription and not the quarterly retesting cadence, and dramatically thinner for someone who wants the monitoring.

Against the concierge tier, it is not a comparison: AgelessRx is a pharmacy with a prescriber, not a diagnostics program. The bands are mapped in concierge vs membership longevity.

Where it stands relative to every graded provider, including the ones we earn nothing from, is on our longevity provider rankings.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). AgelessRx now takes the full four for price transparency — rapamycin, the flagship, publishes a real "$65/month, billed monthly" rate, and while metformin and NAD+ still carry quarterly and introductory qualifiers, the published-terms bar this factor asks is met. Four in full for a genuine longevity line: rapamycin, metformin, NAD+ and sermorelin are a real menu, not a GLP-1 shop with an add-on. Two for a free clinician visit inside every order. Two for the FAQ's unambiguous 503A claim — the single clearest pharmacy-standard statement here, even though no individual facility is named. Zero on human support — there's no bundled nurse or dietitian contact of the kind a support-included program offers. Twelve of fourteen: an A.

That's a real change from where this row used to sit, and it's a change driven entirely by AgelessRx publishing a number it didn't publish before — not by any adjustment to how we score. What still separates a genuinely excellent row from a flawless one: metformin's quarterly-only structure, NAD+'s introductory rate, and a compounding pharmacy that states its standard but never names its facility.

Bottom line

AgelessRx does two things no other row here does at once: it names its prescribers and it publishes trial results that did not go its way. It also removes the two costs that make this category expensive — the membership fee and the mandatory diagnostic onboarding — so a buyer who already knows which molecule they want can get a US-licensed prescriber and a pharmacy without paying a wrapper fee first.

Rapamycin now tells you what it costs — "$65/month, billed monthly," no intake required to find out. Metformin and NAD+ still don't: metformin's real terms are a quarterly prepay, and NAD+'s "$79/mo" is a three-month introductory rate. Buy here if you want the widest legitimate longevity menu with real prescriber oversight, no membership, and a flagship product whose price you can verify before you start. Go in clear-eyed that rapamycin's best human trial, run by this company, missed its primary endpoint, and that metformin, NAD+ and sermorelin are being sold well ahead of their human evidence. Our full graded field, and what each provider actually charges, is at our longevity provider rankings.